-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzamend Neuro FY26 net loss widens 94% to $8.77 million

PUBT·07/22/2026 20:39:42
Listen to the news
Alzamend Neuro FY26 net loss widens 94% to $8.77 million
  • Alzamend Neuro posted a GAAP net loss of USD 8.77 million, widening 94% from the prior fiscal year.
  • Operating loss widened 95% to USD 8.77 million as operating expenses climbed 95% to USD 8.77 million.
  • Research and development expense more than doubled to USD 3.63 million, driven by clinical trial fees of USD 2.93 million.
  • General and administrative costs rose 67% to USD 5.14 million on higher professional fees of USD 2.18 million, including USD 1.9 million in legal fees.
  • Cash was USD 711,000 at April 30, 2026; management flagged substantial doubt about going-concern status within one year of issuance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-008832), on July 22, 2026, and is solely responsible for the information contained therein.